KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zimmer Biomet Holdings (ZBH) Research & Development (2016 - 2025)

Zimmer Biomet Holdings has reported Research & Development over the past 17 years, most recently at $118.7 million for Q4 2025.

  • Quarterly results put Research & Development at $118.7 million for Q4 2025, up 9.4% from a year ago — trailing twelve months through Dec 2025 was $458.5 million (up 4.82% YoY), and the annual figure for FY2025 was $458.5 million, up 4.82%.
  • Research & Development for Q4 2025 was $118.7 million at Zimmer Biomet Holdings, up from $115.9 million in the prior quarter.
  • Over the last five years, Research & Development for ZBH hit a ceiling of $165.0 million in Q2 2021 and a floor of $81.0 million in Q1 2021.
  • Median Research & Development over the past 5 years was $109.9 million (2023), compared with a mean of $109.8 million.
  • Biggest five-year swings in Research & Development: surged 88.98% in 2021 and later tumbled 39.76% in 2022.
  • Zimmer Biomet Holdings' Research & Development stood at $96.0 million in 2021, then grew by 12.5% to $108.0 million in 2022, then increased by 4.91% to $113.3 million in 2023, then dropped by 4.24% to $108.5 million in 2024, then rose by 9.4% to $118.7 million in 2025.
  • The last three reported values for Research & Development were $118.7 million (Q4 2025), $115.9 million (Q3 2025), and $113.3 million (Q2 2025) per Business Quant data.